Thermo Fisher Scientific Inc. $TMO Shares Purchased by Fifth Third Bancorp

Posted by Stanley Muller on Jul 12th, 2026

Fifth Third Bancorp raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 27.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 418,258 shares of the medical research company’s stock after purchasing an additional 89,478 shares during the period. Fifth Third Bancorp’s holdings in Thermo Fisher Scientific were worth $205,586,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Sovran Advisors LLC raised its holdings in Thermo Fisher Scientific by 10.2% in the first quarter. Sovran Advisors LLC now owns 452 shares of the medical research company’s stock valued at $217,000 after acquiring an additional 42 shares in the last quarter. Rossmore Private Capital lifted its position in shares of Thermo Fisher Scientific by 3.2% during the 1st quarter. Rossmore Private Capital now owns 4,865 shares of the medical research company’s stock worth $2,394,000 after purchasing an additional 152 shares during the last quarter. Markel Group Inc. grew its stake in shares of Thermo Fisher Scientific by 6.8% during the first quarter. Markel Group Inc. now owns 67,100 shares of the medical research company’s stock worth $32,982,000 after purchasing an additional 4,300 shares in the last quarter. Signature Resources Capital Management LLC raised its stake in Thermo Fisher Scientific by 89.5% in the first quarter. Signature Resources Capital Management LLC now owns 72 shares of the medical research company’s stock valued at $35,000 after buying an additional 34 shares in the last quarter. Finally, Granite Bay Wealth Management LLC lifted its holdings in Thermo Fisher Scientific by 17.2% during the 1st quarter. Granite Bay Wealth Management LLC now owns 15,447 shares of the medical research company’s stock worth $7,598,000 after buying an additional 2,270 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded up $2.01 during mid-day trading on Friday, reaching $526.72. 1,233,008 shares of the company’s stock were exchanged, compared to its average volume of 1,993,707. The business’s fifty day simple moving average is $478.23 and its 200-day simple moving average is $516.44. The stock has a market capitalization of $195.74 billion, a PE ratio of 28.96, a price-to-earnings-growth ratio of 2.33 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 52-week low of $403.36 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter in the prior year, the business earned $5.15 EPS. Thermo Fisher Scientific’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TMO. Royal Bank Of Canada set a $490.00 target price on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Stifel Nicolaus cut their price objective on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Morgan Stanley restated an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $602.14.

Check Out Our Latest Stock Analysis on TMO

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.